BioSpace News Archive

Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appili’s ATI-1701 program at the Chemical and Biological Defense Science & Technology Conference (CBD S&T)

InterVenn Biosciences, a company in the life sciences and technology sector, is pleased to announce that the interim results of its prospective clinical trial for its Ovarian Cancer Clinical Decision Tool have successfully exceeded its milestones and expectations.

Nkarta Therapeutics announced preclinical data were presented in a poster session at the American Association for Cancer Research, Tumor Immunology and Immunotherapy Meeting 2019 in Boston, Massachusetts.

Technavio has announced its latest market research report titled global x-ray equipment market 2020-2024.

Minnesota Grocery/Pharmacy chain Coborn’s launches their new $9.99 Diabetes Management Program to help customers better afford and manage diabetes.

Therapix Biosciences Ltd. (“Therapix” or the “Company”) (NASDAQ: TRPX), announced today that it entered into a memorandum of understanding (“MOU”) with Heavenly Rx, Ltd. (“Heavenly Rx”), an emerging consumer hemp CBD company, pursuant to which Therapix and Heavenly Rx have agreed to pursue a business combination.

BioArctic AB announced the results of an interim analysis of a Phase 1/2 study of SC0806 in patients with complete spinal cord injury.

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, is proud to announce that they have released the FLUOROspeed X1 edition, patient side conventional RF table system.

Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. and certain of its officers.